BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 17046443)

  • 1. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 2. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
    Nishida T; Yoshidome K; Tori M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG
    Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of imatinib-resistant GIST treated by sunitinib].
    Sakamoto Y; Akimoto H; Kojo M; Kawano H; Chinen Y; Morita K; Sugiyama M; Saeki H; Minami K; Soejima Y; Sakaguchi Y; Toh Y; Okamura T
    Gan To Kagaku Ryoho; 2011 May; 38(5):827-30. PubMed ID: 21566447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hits and misses in targeting pediatric cancers.
    Bernstein ML
    Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
    Kapoor R; Khosla D; Kumar P; Kumar N; Bera A
    J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
    [No Abstract]   [Full Text] [Related]  

  • 11. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
    Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
    von Mehren M; Watson JC
    Oncology (Williston Park); 2009 Jan; 23(1):65-6. PubMed ID: 19283923
    [No Abstract]   [Full Text] [Related]  

  • 14. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H; Nilsson O; Nilsson B
    Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular response prediction in gastrointestinal stromal tumors.
    Cassier PA; Blay JY
    Target Oncol; 2010 Mar; 5(1):29-37. PubMed ID: 20361266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumour.
    Rubin BP; Heinrich MC; Corless CL
    Lancet; 2007 May; 369(9574):1731-41. PubMed ID: 17512858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.